脂肪酸酰胺水解酶
内大麻素系统
阿那达胺
神经炎症
大麻素受体
胶质增生
转基因小鼠
大麻素受体2型
炎症
神经科学
药理学
生物
转基因
受体
医学
免疫学
内科学
生物化学
敌手
基因
作者
Carmen M. Vázquez,Rosa M. Tolón,María T. Grande,Marina Caraza,Marta Fernández,Erin C. Koester,Borja Villaescusa,Lourdes Ruiz‐Valdepeñas,Javier Fernández,Benjamin F. Cravatt,Cecilia J. Hillard,Julián Romero
标识
DOI:10.1016/j.neurobiolaging.2015.08.003
摘要
The modulation of endocannabinoid (EC) levels and the activation of cannabinoid receptors are seen as promising therapeutic strategies in a variety of diseases, including Alzheimer's disease (AD). We aimed to evaluate the effect of the pharmacologic and genetic inhibition of anandamide-degrading enzyme in a mouse model of AD (5xFAD). Pharmacologic inhibition of the fatty acid amide hydrolase (FAAH) had little impact on the expression of key enzymes and cytokines and also on the cognitive impairment, plaque deposition, and gliosis in 5xFAD mice. CB1 blockade exacerbated inflammation in this transgenic mouse model of AD. The genetic inactivation of FAAH led to increases in the expression of inflammatory cytokines. At the same time, FAAH-null 5xFAD mice exhibited a behavioral improvement in spatial memory that was independent of the level of anxiety and was not CB1 mediated. Finally, mice lacking FAAH showed diminished soluble amyloid levels, neuritic plaques, and gliosis. These data reinforce the notion of a role for the EC system in neuroinflammation and open new perspectives on the relevance of modulating EC levels in the inflamed brain.
科研通智能强力驱动
Strongly Powered by AbleSci AI